Greenhouse Gas Emissions and Costs of Inhaler Devices in the US

JAMA. 2024 Sep 24;332(12):1017-1019. doi: 10.1001/jama.2024.15331.
No abstract available

Plain language summary

This study assesses mean emissions and costs and estimated total yearly emissions and costs for US-branded inhalers prescribed to Medicare Part D and Medicaid beneficiaries.

MeSH terms

  • Aerosol Propellants* / chemistry
  • Aerosol Propellants* / economics
  • Asthma / drug therapy
  • Asthma / economics
  • Bronchodilator Agents / administration & dosage
  • Bronchodilator Agents / chemistry
  • Bronchodilator Agents / economics
  • Drug Costs / statistics & numerical data
  • Drug Prescriptions / economics
  • Drug Prescriptions / statistics & numerical data
  • Fluorocarbons / chemistry
  • Fluorocarbons / economics
  • Greenhouse Effect* / economics
  • Greenhouse Effect* / prevention & control
  • Greenhouse Gases* / chemistry
  • Greenhouse Gases* / economics
  • Humans
  • Medicaid / economics
  • Medicaid / statistics & numerical data
  • Medicare Part D / economics
  • Medicare Part D / statistics & numerical data
  • Nebulizers and Vaporizers* / economics
  • Nebulizers and Vaporizers* / statistics & numerical data
  • Pulmonary Disease, Chronic Obstructive / drug therapy
  • Pulmonary Disease, Chronic Obstructive / economics
  • United States

Substances

  • Greenhouse Gases
  • Aerosol Propellants
  • Fluorocarbons
  • Bronchodilator Agents